Cantor Fitzgerald Reiterates Overweight on Lyra Therapeutics
Portfolio Pulse from Benzinga Newsdesk
Cantor Fitzgerald analyst Louise Chen has reiterated an Overweight rating on Lyra Therapeutics (NASDAQ:LYRA).
June 20, 2024 | 5:40 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Cantor Fitzgerald analyst Louise Chen has reiterated an Overweight rating on Lyra Therapeutics, indicating a positive outlook for the stock.
The reiteration of an Overweight rating by a reputable analyst suggests confidence in the company's future performance, likely leading to a positive short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100